Eligibility
Use the eligibility guidance when the main question is whether tirzepatide makes clinical sense and what can block a start.
Coverage depends on your exact plan, clinician, location and service. Check participation and expected charges with the clinic and your insurer before booking.
Tirzepatide for weight management is generally reviewed for adults with obesity, or adults with overweight plus a weight-related medical condition, alongside a reduced-calorie diet and increased physical activity. Some adults with obesity and moderate to severe obstructive sleep apnea may also fall within current FDA-approved use. The real decision still depends on medical history, current medications, GI tolerance, thyroid-cancer risk factors, and whether another GLP-1 path already makes more sense.
Good tirzepatide care is not just a prescription. It usually means slow dose escalation, side-effect review, appetite and hydration check-ins, constipation or nausea management, weight and symptom tracking, and clear guidance on when to hold, continue, or escalate the dose.
Tirzepatide is the ingredient in Mounjaro and Zepbound. Mounjaro is approved with diet and exercise to improve glucose control in adults and children age 10 and older with type 2 diabetes. Under its August 2026 US label, it also reduces the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk. These events are cardiovascular death, nonfatal heart attack or nonfatal stroke. That cardiovascular indication is for adults. Zepbound has separate approvals for adult weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. These approvals do not extend to compounded tirzepatide.
Tirzepatide activates GIP and GLP-1 receptors. It helps glucose regulation and reduces appetite. Its two brand names have different approved indications; the ingredient alone does not establish insurance coverage.
Zepbound weight treatment is for adults with obesity or overweight and a weight-related condition. The OSA indication needs the specified diagnosis and obesity. Mounjaro’s pediatric diabetes approval does not create a pediatric Zepbound weight indication.
Review the diagnosis, medicine history and risks. Both approved tirzepatide brands start at 2.5 mg once weekly, but follow their separate schedules. The August 2026 Mounjaro label permits 2.5 mg increases after at least four weeks on the current dose if additional glucose control is needed. Its maximum is 15 mg weekly for adults and 10 mg for pediatric patients. Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg. Its maintenance dose depends on weight or OSA treatment and tolerability. Increase only under the prescriber’s plan. Train for the exact vial or pen received and arrange monitoring and refills.
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. Use a non-oral contraceptive method or add a barrier method for four weeks after starting tirzepatide and after each dose increase. Do not overlap tirzepatide products or another GLP-1 medicine without a clinician’s plan.
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
In a weight-management program, the FDA-approved Zepbound product is used with reduced-calorie eating and increased physical activity for qualifying adults. Tirzepatide in Mounjaro has diabetes indications, so the brands and uses should not be assumed interchangeable. The clinician confirms suitability, dose escalation, response and safety rather than prescribe from a weight goal alone.
Zepbound weight treatment is for adults with obesity or overweight and a weight-related condition. The OSA indication needs the specified diagnosis and obesity. Mounjaro’s pediatric diabetes approval does not create a pediatric Zepbound weight indication.
The visit, laboratory tests, and medicine can have different coverage rules. Ask the plan about the exact brand and indication, exclusions, prior authorization, required records, deductible, copay, and dispensing route. Bring a denial for review of its specific reason. Nao Medical or the prescriber cannot guarantee approval. Confirm current participation and costs before booking.
Semaglutide activates GLP-1 receptors; tirzepatide activates GIP and GLP-1 receptors. Their diabetes and weight brands have different indications and instructions. Foundayo contains orforglipron, another GLP-1 medicine. Metformin acts differently. Choose the exact medicine for the clinical goal rather than treating them as interchangeable.
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
A switch needs review of the exact product, dose, time on treatment, response, side effects, nutrition, and access. A plateau alone does not mean you must change medicines. The prescriber sets a transition and titration plan. Do not overlap products or convert milligrams yourself.
Both are once-weekly tirzepatide injections given under the skin of the abdomen or thigh, or in the back of the upper arm with another person’s help. Rotate sites. Use the Instructions for Use for the exact brand and device dispensed: a single-dose pen, single-dose vial, multidose vial and KwikPen require different handling. Get a demonstration before starting or changing devices. Never share a KwikPen. The Mounjaro label does not recommend KwikPen self-administration by pediatric patients or people with visual impairment. Do not mix Mounjaro with insulin in one syringe or estimate a vial dose from another product’s directions.
Mounjaro is an Eli Lilly and Company medicine containing tirzepatide. Zepbound is another Lilly tirzepatide brand with different approved uses. A compounded tirzepatide product is not branded Mounjaro.
It is a medicine prepared by a compounder for a particular clinical need rather than a finished FDA-approved Mounjaro or Zepbound product. The compounded preparation is not FDA approved or established as an interchangeable equivalent. Its concentration, packaging and instructions can differ. FDA advises using compounded GLP-1 drugs only when an approved drug cannot meet the patient’s medical need. Ask the prescriber why it is needed and use a licensed pharmacy. Do not buy research-use products or assume an ingredient name proves equivalent quality.
Use the eligibility guidance when the main question is whether tirzepatide makes clinical sense and what can block a start.
Use the cost details when the real question is prior authorization, self-pay, pharmacy pricing, or what insurance may actually cover.
Use the monitoring guidance when patients need clarity on dose escalation, follow-up cadence, and how side effects are managed.
Use the comparison guide when the decision is not just whether to start, but which GLP-1 path fits better.
Bronx
932 E 174th St, Bronx, NY 10460
A Bronx access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in West Farms, Crotona Park East, and nearby Bronx neighborhoods.
View local weight-loss details Get directions
Queens
37-15 23rd Ave, Astoria, NY 11105
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods.
View local weight-loss details Get directions
Bronx
2063A Bartow Ave, Bronx, NY 10475
A Bronx access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods.
View local weight-loss details Get directions
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A Brooklyn access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods.
View local weight-loss details Get directions
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A Long Island access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Hicksville, Plainview, Bethpage, and nearby Nassau County communities.
View local weight-loss details Get directions
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods.
View local weight-loss details Get directions
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods.
View local weight-loss details Get directions
Queens
30-07 36th Ave, Astoria, NY 11106
A Queens access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods.
View local weight-loss details Get directions
Long Island
135 Mineola Blvd, Mineola, NY 11501
A Long Island access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Mineola, Garden City, Westbury, and nearby Nassau County communities.
View local weight-loss details Get directions
Manhattan
259 1st Ave, New York, NY 10003
A Manhattan access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in StuyTown, East Village, Gramercy, and nearby Manhattan neighborhoods.
View local weight-loss details Get directions
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A Brooklyn access point for provider-guided tirzepatide evaluation, medication follow-up, and practical weight-loss visits for patients in Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods.
View local weight-loss details Get directionsThe current parent overview remains the broad entry point for medical weight-loss care across NYC and Long Island.
Use the broader program guidance when the first question is overall medical weight loss, not only tirzepatide.
Use the semaglutide guidance when patients still need the other GLP-1 medication option directly.
Use Zepbound guidance when patients ask by brand name and needs direct answers on insurance, self-pay, availability, and Wegovy comparison.
Patients who still need the semaglutide side of the family can move directly into the existing overview details.
Insurance friction is often the practical blocker, so the live coverage guide is still relevant alongside this tirzepatide treatment path.
Medication choice also depends on refill stability and fulfillment, not just the first prescription.
Arrange an evaluation to discuss suitable care, preparation and follow-up with a clinician.
Start with eligibility